Effector Historical Income Statement
| EFTR Stock | USD 1.89 0.10 5.03% |
Historical analysis of Effector Therapeutics income statement accounts such as Other Operating Expenses of 33.6 M or Research Development of 17.8 M can show how well Effector Therapeutics performed in making a profits. Evaluating Effector Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Effector Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Effector Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Effector Therapeutics is a good buy for the upcoming year.
Effector |
About Effector Income Statement Analysis
Effector Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Effector Therapeutics shareholders. The income statement also shows Effector investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Effector Therapeutics Income Statement Chart
Effector Therapeutics Income Statement is one of the three primary financial statements used for reporting Effector's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Effector Therapeutics revenue and expense. Effector Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Effector Therapeutics' Depreciation And Amortization is relatively stable compared to the past year. As of 04/18/2024, Interest Income is likely to grow to about 1 M, though Interest Expense is likely to grow to (2.8 M). Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Effector Therapeutics. It is also known as Effector Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Cost Of Revenue
Cost of Revenue is found on Effector Therapeutics income statement and represents the costs associated with goods and services Effector Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Most accounts from Effector Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Effector Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Effector Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Effector Stock, please use our How to Invest in Effector Therapeutics guide.At this time, Effector Therapeutics' Depreciation And Amortization is relatively stable compared to the past year. As of 04/18/2024, Interest Income is likely to grow to about 1 M, though Interest Expense is likely to grow to (2.8 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 31.9M | 32.4M | 33.7M | 33.6M | Cost Of Revenue | 24K | 53K | 111K | 105.5K |
Effector Therapeutics income statement Correlations
Click cells to compare fundamentals
Effector Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Effector Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Effector Therapeutics' short interest history, or implied volatility extrapolated from Effector Therapeutics options trading.
Pair Trading with Effector Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Effector Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Effector Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Effector Stock
| 0.72 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
| 0.63 | KZR | Kezar Life Sciences Financial Report 9th of May 2024 | PairCorr |
Moving against Effector Stock
| 0.42 | MRKR | Marker Therapeutics | PairCorr |
The ability to find closely correlated positions to Effector Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Effector Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Effector Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Effector Therapeutics to buy it.
The correlation of Effector Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Effector Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Effector Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Effector Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Effector Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Effector Stock, please use our How to Invest in Effector Therapeutics guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Complementary Tools for Effector Stock analysis
When running Effector Therapeutics' price analysis, check to measure Effector Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Effector Therapeutics is operating at the current time. Most of Effector Therapeutics' value examination focuses on studying past and present price action to predict the probability of Effector Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Effector Therapeutics' price. Additionally, you may evaluate how the addition of Effector Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Stocks Directory Find actively traded stocks across global markets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |
Is Effector Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Effector Therapeutics. If investors know Effector will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Effector Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (16.37) | Revenue Per Share 0.349 | Quarterly Revenue Growth 1.17 | Return On Assets (0.85) | Return On Equity (9.47) |
The market value of Effector Therapeutics is measured differently than its book value, which is the value of Effector that is recorded on the company's balance sheet. Investors also form their own opinion of Effector Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Effector Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Effector Therapeutics' market value can be influenced by many factors that don't directly affect Effector Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Effector Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Effector Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Effector Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.